| Literature DB >> 31730857 |
Daniel P Hollern1, Nuo Xu2, Aatish Thennavan3, Cherise Glodowski4, Susana Garcia-Recio1, Kevin R Mott1, Xiaping He1, Joseph P Garay1, Kelly Carey-Ewend1, David Marron1, John Ford1, Siyao Liu1, Sarah C Vick2, Miguel Martin5, Joel S Parker1, Benjamin G Vincent6, Jonathan S Serody7, Charles M Perou8.
Abstract
This study identifies mechanisms mediating responses to immune checkpoint inhibitors using mouse models of triple-negative breast cancer. By creating new mammary tumor models, we find that tumor mutation burden and specific immune cells are associated with response. Further, we developed a rich resource of single-cell RNA-seq and bulk mRNA-seq data of immunotherapy-treated and non-treated tumors from sensitive and resistant murine models. Using this, we uncover that immune checkpoint therapy induces T follicular helper cell activation of B cells to facilitate the anti-tumor response in these models. We also show that B cell activation of T cells and the generation of antibody are key to immunotherapy response and propose a new biomarker for immune checkpoint therapy. In total, this work presents resources of new preclinical models of breast cancer with large mRNA-seq and single-cell RNA-seq datasets annotated for sensitivity to therapy and uncovers new components of response to immune checkpoint inhibitors.Entities:
Keywords: B cells; CTLA4; PD1; T cells; TMB; breast cancer; genomics; immune checkpoints; immunotherapy; mouse models; tumor mutation burden
Mesh:
Substances:
Year: 2019 PMID: 31730857 PMCID: PMC6911685 DOI: 10.1016/j.cell.2019.10.028
Source DB: PubMed Journal: Cell ISSN: 0092-8674 Impact factor: 41.582